Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With... Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods: Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results: Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion: Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/phase-ii-and-biomarker-study-of-the-dual-met-vegfr2-inhibitor-4n6oeMroRy

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
(C) 2013 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.2012.43.3383
Publisher site
See Article on Publisher Site

Abstract

Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods: Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results: Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion: Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.

Journal

Journal of Clinical Oncology – Wolters Kluwer Health

Published: Jan 10, 2013

References

  • Cancer statistics, 2010
    A Jemal; R Siegel; J Xu
  • Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors
    B Delahunt; JN Eble
  • Novel mutations of the MET proto-oncogene in papillary renal carcinomas
    L Schmidt; K Junker; N Nakaigawa
  • Papillary renal tumors
    DJ Lager; BJ Huston; TG Timmerman
  • Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
    L Schmidt; FM Duh; F Chen
  • Novel therapeutic inhibitors of the c-Met signaling pathway in cancer
    JP Eder; GF Vande Woude; SA Boerner
  • Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases
    F Qian; S Engst; K Yamaguchi
  • A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
    JP Eder; GI Shapiro; LJ Appleman
  • A phase I dose escalation study of the safety and pharmacokinetics of once-daily foretinib, a multikinase inhibitor, in patients with solid tumors
    GI Shapiro; S McCallum; LM Adams
  • WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects World Medical Association (WMA)
    WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects World Medical Association (WMA)
  • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse; SG Arbuck; EA Eisenhauer
  • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    RJ Motzer; J Bacik; BA Murphy
  • Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    TK Choueiri; A Plantade; P Elson
  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial
    ME Gore; C Szczylik; C Porta
  • Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    WM Stadler; RA Figlin; DF McDermott
  • A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
    NM Tannir; E Plimack; C Ng
  • First-line sunitinib in type I and papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)
    A Ravaud; S Oudard; DR Fromont
  • Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    AM Molina; DR Feldman; MS Ginsberg
  • Multicenter phase II study of sunitinib in patients with non-clear cell type renal cell carcinoma
    J Lee; J Ahn; H Lim
  • Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    JP Dutcher; P de Souza; D McDermott
  • Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis
    SR Nalluri; D Chu; R Keresztes
  • Risk of venous thromboembolic events with sunitinib and sorafenib: A systemic review and meta-analysis of clinical trials
    FA Schutz; JE Rosenberg; Y Je
  • Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target
    C Vaklavas; D Lenihan; R Kurzrock